Skip to main content
main-content

Genetics

Genetics

02-07-2020 | Oncology | News | Article

Support for ‘plasma-first’ approach in molecular testing for NSCLC

Comprehensive circulating tumor DNA analysis can identify therapeutically targetable driver and resistance mutations in patients with advanced non-small-cell lung cancer, research indicates.

29-06-2020 | Oncology | News | Article

Entrectinib receives positive decision from EMA

More details about the announcement are a click away

01-05-2020 | Oncology | News | Article

Larotrectinib response best with NTRK fusion mutations

Solid tumor patients with NTRK fusion mutations experience “robust and durable responses” to treatment with larotrectinib, but those with other types of NTRK alterations derive “limited benefit” from the selective TRK inhibitor, investigators say.

15-04-2020 | Oncology | News | Article

Long noncoding RNA signatures may help predict immunotherapy response

Chinese researchers have used a combination of long noncoding RNA signatures and cytotoxic T-lymphocyte tumor infiltration to identify four distinct immune classes that may predict response to cancer immunotherapy.

13-11-2019 | Oncology | News | Article

HLA-I evolutionary divergence linked to ICI response in cancer

HLA class I evolutionary divergence is associated with response to immune checkpoint inhibitor treatment in people with cancer, show data published in Nature Medicine.

15-10-2019 | Oncology | News | Article

Value of blood-based screening for ALK fusions shown in patients with NSCLC

Blood-based next-generation sequencing can be used to identify patients with non-small-cell lung cancer and ALK fusions who will benefit from treatment with alectinib, show results of the phase II/III blood-first assay screening trial.

10-10-2019 | Oncology | News | Article

PROfound paves the way for precision medicine in mCRPC

Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.

08-07-2019 | Rheumatology | News | Article

RA genetic risk linked to IQ, hyperactivity during childhood

Genetic liability for rheumatoid arthritis is associated with lower IQ and symptoms of hyperactivity and inattention during childhood and adolescence, supporting a link between genetic risk for the condition and neural phenotypes, UK researchers report.

22-01-2019 | Oncology | News | Article

Mutational load predicts immunotherapy response across most tumor types

Tumor mutational burden could be a cross-tumor predictive biomarker of immunotherapy, say US researchers who found an association between mutational load and survival across a wide range of malignancies treated with immune checkpoint inhibitors.

16-01-2019 | Prostate cancer | News | Article

Germline BRCA2 mutations impact mCRPC survival

Germline mutations in the BRCA2 gene, but not other DNA damage repair genes, are associated with poorer outcomes among patients with metastatic castration-resistant prostate cancer, study findings indicate.

11-01-2019 | Oncology | News | Article

COMT gene modifies chemopreventive effects of vitamin E

Vitamin E supplementation may reduce the risk for cancer but only in individuals harboring a particular allele of the catechol-O-methyltransferase gene, suggests an analysis of two randomized trials.

20-12-2018 | Asthma | News | Article

Genetic variants linked to moderate-to-severe asthma susceptibility

A genome-wide association study has identified novel genetic variants associated with the risk of developing moderate-to-severe asthma, a substantial proportion of which are also associated with mild asthma susceptibility.

19-09-2018 | Oncology | News | Article

Persistent mutations post-transplant predict MDS disease progression

Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.

23-08-2018 | Oncology | News | Article

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.

09-08-2018 | Non-small-cell lung cancer | News | Article

Broad-based genomic screening benefits questioned for advanced NSCLC

Most patients being treated in the community setting for advanced nonsquamous non-small-cell lung cancer do not benefit from the use of broad-based genomic sequencing, suggests a study comparing this approach with routine testing for only epidermal growth factor receptor and anaplastic lymphoma kinase alterations.

08-08-2018 | Non-small-cell lung cancer | News | Article

Molecular mechanisms of acquired osimertinib resistance explored

An analysis of patients with T790M-positive, advanced non-small-cell lung cancer who developed resistance to osimertinib points to heterogeneous underlying molecular mechanisms.

30-07-2018 | Breast cancer | News | Article

TGFB1 gene key determinant of breast fibrosis risk

Carriers of the C−509T allele in the transforming growth factor ß 1 gene have a significantly increased risk for late breast fibrosis following breast-conserving surgery and whole-breast irradiation for stage 0 to IIA breast cancer, researchers report.

11-05-2018 | Breast cancer | News | Article

Germline BRCA status may influence advanced TNBC chemotherapy choice

Testing for BRCA1 and BRCA2 mutations could inform the choice of chemotherapeutic agent in women with advanced triple-negative breast cancer, suggest the results of the TNT trial.

11-04-2018 | Non-small-cell lung cancer | News | Article

Concomitant mutations linked to poorer response in EGFR mutation-positive NSCLC

In patients with epidermal growth factor receptor-mutated non-small-cell lung cancer, the presence of concomitant mutations in other cancer-related genes is associated with worse outcomes in response to EGFR tyrosine kinase inhibitors, Chinese research suggests.

11-04-2018 | Leukaemia | News | Article

Molecular minimal residual disease predicts poor outcome in AML

The presence of molecular minimal residual disease, identified by next-generation targeted sequencing, is associated with a significantly increased risk for relapse or death in patients with acute myeloid leukemia, study findings indicate.

Image Credits